• Main
  • Useful links
  • Information for Contributors
  • About
  • Editorial board

  • Article
    O.S. Khukhlina, A.A Antoniv, I.V. Dudka, T.V. Dudka, O.E. Mandryk


    About the author: O.S. Khukhlina, A.A Antoniv, I.V. Dudka, T.V. Dudka, O.E. Mandryk
    Type of article Scentific article
    Annotation The study was aimed to find out the possible interaction of the blood lipid spectrum, the level of glycemia and the degree of insulin resistance on the clinical course of non-alcoholic steatohepatitis (NASH) on the background of obesity, depending on the presence of comorbid hypertensive disease (HD) II stage. The total of 90 patients with NASH were examined: of which 30 patients with NASH and obesity I degree (1 group), 30 patients with NASH and a comorbid flow of HD II stage and obesity I degree (group 2), 30 patients with HD II stage and obesity I degree (group 3). The studies of lipid spectrum in blood in patients with NASH showed results of the lipid spectrum of the blood and the insulin resistance degree in patients with non-alcoholic steatohepatitis and comorbidity with obesity and hypertension disease second degree. In patients with non-alcoholic steatohepatitis and obesity without accompanying hypertension, the following changes in the blood lipid profile are characteristic: the maximum increase in the content of triacylglycerol in the blood, the likely increase in the content of total cholesterol and low proatherogenic lipoproteins, the probable decrease in anti-atherogenic high-density lipoproteins, which, with the addition of the comorbid HDII stage it is likely to deepen, in addition to the indicator of hypertriacylglycerolemia. The reason for the progression of the metabolic syndrome against non-alcoholic steatohepatitis and hypertension is lipid distress syndrome with an increase in total blood cholesterol, low proatherogenic lipoprotein, and a deficiency of high-density anti-atherogenic lipoprotein.
    Tags nonalcoholic steatohepatitis, obesity, hypertonic disease, blood lipid spectrum, insulin resistance
    • Fadeenko GD, Prosolenko KA, Kolesnikova EV. The role of obesity as a component of the metabolic syndrome in the onset and progression of nonalcoholic fatty liver disease. Modern gastroenterol. 2008; (2): 4-10.
    • Kharchenko NV, Anokhin GA, Chekman SI, et al. Hepatoprotectors in the treatment of liver diseases: clinical and biochemical mechanisms of action. News of medicine and pharmacy. Gastroenterology. 2013; (457).
    • Kolesnikova OV., Dubrov KY, Krakhmalova EO. Relationship between non-alcoholic steatosis of the liver, insulin resistance and anthropometric indices in patients with signs of a metabolic syndrome. Ukr therapist. Journ 2010; (3): 81-86.
    • Svintsitsky AU, Kozak NP, Barabanchik OV, Mykhchak MZ. Hyperuricemia and its role in the development of metabolic syndrome. Practitioner. 2013; (3) (special issue): 83-85.
    • Zvyagintseva TD, Glushchenko SV. L-carnitine and oxidative stress - stress in non-alcoholic steatohepatite. The 41st Scientific session of the Central Scientific Research Institute "Enlarging the Borders". 2015: 19-20.
    • Bhala N, Angulo Р, van der Poorten D. et al. The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: An international collaborative study. Hepatology. 2012; 54 (4): 1208–1216.
    • Brunt EM, Kleiner DE, Wilson LA Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology. 2011;( 53(3)): 810-820.
    • Pagadala MR, McCullough AJ. The relevance of liver histology to predicting clinically meaningful outcomes in nonalcoholic steatohepatitis. Clinical liver Disease. 2012;Vol.16, №3: 487-504.
    • Torres DM, Harrison SA. Diagnosis and therapy of nonalcoholic steatohepatitis. Gastroenterology. 2008; 134 (6): 1682–1698. 
    Publication of the article «World of Medicine and Biology» №2(64), 2018 year, 085-088 pages, index UDK 616.153:616.36-003.826:616-056.527
    DOI 10.26724/2079-8334-2018-2-64-85-88